Compare BBWI & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBWI | NAMS |
|---|---|---|
| Founded | 1963 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.5B |
| IPO Year | 1994 | N/A |
| Metric | BBWI | NAMS |
|---|---|---|
| Price | $20.20 | $30.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 8 |
| Target Price | $25.61 | ★ $46.75 |
| AVG Volume (30 Days) | ★ 5.1M | 812.0K |
| Earning Date | 06-02-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.91% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.17 | N/A |
| Revenue | ★ $7,307,000,000.00 | N/A |
| Revenue This Year | N/A | $25.64 |
| Revenue Next Year | $2.91 | $530.85 |
| P/E Ratio | $17.58 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.28 | $14.06 |
| 52 Week High | $34.29 | $42.00 |
| Indicator | BBWI | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 38.17 | 39.63 |
| Support Level | $19.15 | $30.34 |
| Resistance Level | $20.36 | $37.43 |
| Average True Range (ATR) | 1.17 | 1.72 |
| MACD | -0.37 | -0.41 |
| Stochastic Oscillator | 2.47 | 20.05 |
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with just 5% of sales from international markets in fiscal 2024. For fiscal 2024, 76% of sales stemmed from the brick-and-mortar network (which was composed of more than 1,800 retail stores), similar to 2023 levels, as consumer shopping patterns remained to normal. Future growth is expected from store upgrades, digital and international channels, as well as adjacent category expansions like men's and lip.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.